Patent ID: 9206256
Filing Date: 2015-12-08
Classification: A61K,A61P,C07K

Abstract:
1. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds to the extracellular domain of human discoidin domain receptor 1 (DDR1), wherein the cancer expresses DDR1 and the antibody comprises: (a) a heavy chain CDR1 comprising GYTFTDYFMK (SEQ ID NO:22), a heavy chain CDR2 comprising DINPNNGDTFYIQKFKG (SEQ ID NO:23), and a heavy chain CDR3 comprising SRDLAY (SEQ ID NO:24) and (b) a light chain CDR1 comprising KSSQSLLYSNGKTYLN (SEQ ID NO:27), a light chain CDR2 comprising QVSKLDS (SEQ ID NO:28), and a light chain CDR3 comprising VQGTDFPQT (SEQ ID NO:29).